Randomized Trials
Perspective: The need for increased pragmatism in cardiovascular clinical trials.
19 May, 2022 | 10:48h | UTCThe need for increased pragmatism in cardiovascular clinical trials – Nature Reviews Cardiology (if the link is paywalled, try this one)
Related: A roadmap of strategies to support cardiovascular researchers: from policy to practice – Nature Reviews Cardiology (if the link is paywalled, try this one)
Commentary on Twitter
In our latest Review, @ShahzebKhanMD and colleagues discuss the need for increased pragmatism in #cardiovascular clinical trials: https://t.co/LUlrPKusAk pic.twitter.com/cxAYmD2nyS
— Nature Reviews Cardiology (@NatRevCardiol) May 17, 2022
Study designs for clinical trials applied to personalized medicine: a scoping review.
19 May, 2022 | 10:36h | UTCStudy designs for clinical trials applied to personalised medicine: a scoping review – BMJ Open
Visualizing harms in publications of randomized controlled trials: consensus and recommendations.
17 May, 2022 | 10:47h | UTCCommentary: Visualising harms: barely scratching the surface – The BMJ
RCT: Efficacy and safety of fenfluramine for the treatment of seizures associated With Lennox-Gastaut Syndrome.
16 May, 2022 | 01:29h | UTCCommentaries:
Fenfluramine Found Effective for Treatment of Lennox-Gastaut Syndrome Seizures – NeurologyToday
Fenfluramine Seems Effective for Lennox-Gastaut Syndrome – HealthDay
Commentary on Twitter
In this randomized clinical trial, fenfluramine was a safe and effective treatment option for patients with Lennox-Gastaut syndrome. https://t.co/Ukopx9cV9r @Zogenix pic.twitter.com/dRetoOZSiB
— JAMA Neurology (@JAMANeuro) May 2, 2022
Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilization: RCT and systematic review.
12 May, 2022 | 07:53h | UTCRelated:
Phase 2 RCT: Anti-tumor necrosis factor therapy for early-stage Dupuytren’s disease.
9 May, 2022 | 01:38h | UTCNews Release: Breakthrough in treatment for Dupuytren’s disease – University of Oxford
Commentary: Treatment for finger-bending disease may be ‘gamechanger’ – The Guardian
Commentary on Twitter
NEW RESEARCH—Intranodular injections of anti-tumour necrosis factor therapy (adalimumab) for early-stage Dupuytren's disease: a phase 2b, randomised, double-blind, placebo-controlled trial https://t.co/Jz9QUJEzS8 #LancetRheumatology #OpenAccess pic.twitter.com/mcZj9GK4l4
— The Lancet Rheumatology (@TheLancetRheum) May 4, 2022
RCT: Reloxaliase vs. placebo in enteric hyperoxaluria.
9 May, 2022 | 01:30h | UTCRandomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria – NEJM Evidence
Commentary on Twitter
Patients with enteric hyperoxaluria received reloxaliase, an enzyme that degrades oxalate in the GI tract, or placebo with food for 4 weeks. There was a greater reduction in urinary oxalate excretion with reloxaliase. https://t.co/x7m12QHyWX#NephTwitter #UroSoMe #ClinicalTrials pic.twitter.com/rzCpd6YfLM
— NEJM Evidence (@NEJMEvidence) May 6, 2022
RCT: Efficacy and safety of Difelikefalin in patients with moderate to severe pruritus receiving hemodialysis.
9 May, 2022 | 01:21h | UTC
Commentary on Twitter
This RCT found difelikefalin, a κ-opioid receptor agonist, improved moderate to severe pruritus in Japanese hemodialysis patients. Difelikefalin is expected to be a new option for the treatment of uremic pruritus in patients with end stage kidney disease. https://t.co/cXqNx4QIaS pic.twitter.com/7QdA9GoLwN
— JAMA Network Open (@JAMANetworkOpen) May 5, 2022
Non-Inferiority Trials: Understanding the concepts.
1 May, 2022 | 23:33h | UTCNon-Inferiority Trials: Understanding the Concepts – Students 4 Best Evidence
Related:
Non-inferiority trials in cardiology: what clinicians need to know – Heart
RCT: Hybrid vs. open surgical reconstruction for iliofemoral occlusive disease.
1 May, 2022 | 23:28h | UTC
RCT: Substrate ablation vs. antiarrhythmic drug therapy for symptomatic ventricular tachycardia.
20 Apr, 2022 | 09:46h | UTCSubstrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Podcast: Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia
RCT: Sintilimab vs. placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic esophageal squamous cell carcinoma.
20 Apr, 2022 | 09:28h | UTC
Commentary on Twitter
Compared with placebo, sintilimab in combination with chemo showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma, finds study https://t.co/m8Gn3SBmCu
— The BMJ (@bmj_latest) April 19, 2022
RCT: Allopurinol is noninferior to febuxostat for controlling gout flares.
19 Apr, 2022 | 02:05h | UTCComparative Effectiveness of Allopurinol and Febuxostat in Gout Management – NEJM Evidence (link to abstract – $ for full-text)
Cluster RCT: BABEL (Better tArgeting, Better outcomes for frail ELderly patients) advance care planning: a comprehensive approach to advance care planning in nursing homes.
19 Apr, 2022 | 01:26h | UTC
10-year results of a phase 3 RCT: High-dose radiotherapy and risk-adapted androgen deprivation in localized prostate cancer.
19 Apr, 2022 | 01:22h | UTCHigh-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial – The Lancet Oncology (link to abstract – $ for full-text)
RCT: Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children.
14 Apr, 2022 | 08:43h | UTCEfficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
RCT: A home-based, walking exercise behavior change intervention increased walking distance in adults with peripheral artery disease.
13 Apr, 2022 | 11:02h | UTCEffect of a Home-Based, Walking Exercise Behavior Change Intervention vs Usual Care on Walking in Adults With Peripheral Artery Disease: The MOSAIC Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
In this study, among adults with peripheral artery disease, a home-based, #walking #exercise behavior change intervention, compared with usual care, increased 6-minute walking distance at 3 months. https://t.co/5ea3YOWlN0 @LindsayBearne pic.twitter.com/s06ONnki9y
— JAMA (@JAMA_current) April 12, 2022
RCT: In patients undergoing knee replacement surgery, the administration of periarticular liposomal bupivacaine did not improve postoperative recovery or pain compared with bupivacaine hydrochloride alone.
13 Apr, 2022 | 10:16h | UTC
RCT: Prophylactic Rivaroxaban for 30 days to prevent left ventricular thrombus after anterior ST-Segment Elevation Myocardial Infarction.
13 Apr, 2022 | 09:56h | UTCProphylactic Rivaroxaban Therapy for Left Ventricular Thrombus After Anterior ST-Segment Elevation Myocardial Infarction – JACC: Cardiovascular Interventions (link to abstract – $ for full-text)
RCT: Efficacy and safety of AbobotulinumtoxinA in patients with neurogenic detrusor overactivity incontinence performing regular clean intermittent catheterization.
12 Apr, 2022 | 08:42h | UTC
RCT: Efficacy and safety of weekly somatrogon vs. daily somatropin in children with growth hormone deficiency.
12 Apr, 2022 | 08:34h | UTC
RCT: Prophylactic Penehyclidine inhalation for prevention of postoperative pulmonary complications in high-risk patients.
12 Apr, 2022 | 08:18h | UTC
RCT: For adults with HIV, a 4-days-on and 3-days-off treatment strategy is noninferior to standard treatment for maintaining viral suppression.
11 Apr, 2022 | 01:56h | UTCA 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial – The Lancet HIV (link to abstract – $ for full-text)
Commentary: Intermittent Treatment Strategy Is Effective for HIV – Consultant360
Commentaries on Twitter
New: A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial by Roland Landman and colleagues https://t.co/Tc2Rbo1ISt pic.twitter.com/YTV3XwfELo
— The Lancet HIV (@TheLancetHIV) February 3, 2022
In virologically suppressed people with HIV, randomization to intermittent ART (4 days on, 3 off) was non-inf. to daily dosing. Challenges what I thought about level of adherence needed. Is good adherence only needed during the viremic phase? https://t.co/lM8QZW0C9h
— David Serota (@serotavirus) March 16, 2022
RCT: Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough.
11 Apr, 2022 | 01:22h | UTCEfficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
For refractory chronic cough or unexplained chronic cough, gefapixant 45 mg twice per day is the first treatment to show efficacy with an acceptable safety profile in phase 3 clinical trials.
New study by Lorcan P McGarvey & colleagues: https://t.co/XnWM75s6lN pic.twitter.com/VyYyRgWTod
— The Lancet (@TheLancet) March 7, 2022
Study Commentary | To Bougie or not to Bougie: Bougie vs. Stylet for first-pass intubation success.
8 Apr, 2022 | 10:07h | UTC